Preparation and biological evaluation of copper-64-labeled Tyr3 -: Octreotate using a cross-bridged macrocyclic chelator

被引:151
作者
Sprague, JE
Peng, YJ
Sun, XK
Weisman, GR
Wong, EH
Achilefu, S
Anderson, CJ
机构
[1] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA
[2] Univ New Hampshire, Dept Chem, Durham, NH 03824 USA
关键词
D O I
10.1158/1078-0432.CCR-04-1084
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Somatostatin receptors (SSTr) are expressed on many neuroendocrine tumors, and several radiotracers have been developed for imaging these types of tumors. For this reason, peptide analogues of somatostatin have been well characterized. Copper-64 (t(1/2) = 12.7 hours), a positron emitter suitable for positron emission tomography (PET) imaging, was shown recently to have improved in vivo clearance properties when chelated by the cross-bridged tetraazamacrocycle 4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo(6.6.2)hexadecane (CB-TE2A) compared with 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA). Experimental Design: CB-TE2A and TETA were conjugated to the somatostatin analogue tyrosine-3-octreotate (Y3-TATE) for evaluation of CB-TE2A as a bifunctional chelator of Cu-64. The in vitro affinity of each compound for SSTr was determined using a homologous competitive binding assay. In vivo characteristics of both radiolabeled compounds were examined in biodistribution and microPET studies of AR42J tumor-bearing rats. Results: Cu-CB-TE2A-Y3-TATE (K-d = 1.7 nmol/L) and Cu-TETA-Y3-TATE (K-d = 0.7 nmol/L) showed similar affinities for AR42J derived SSTr. In biodistribution studies, nonspecific uptake in blood and liver was lower for Cu-64-CB-TE2A-Y3-TATE. Differences increased with time such that, at 4 hours, blood uptake was 4.3-fold higher and liver uptake was 2.4-fold higher for Cu-64-TETA-Y3-TATE than for Cu-64-CB-TE2A-Y3-TATE. In addition, 4.4-times greater tumor uptake was detected with Cu-64-CB-TE2A-Y3-TATE than with Cu-64-TETA-Y3-TATE at 4 hours postinjection. MicroPET imaging yielded similar results. Conclusions: CB-TE2A appears to be a superior in vivo bifunctional chelator Of (CU)-C-64 for use in molecular imaging by PET or targeted radiotherapy due to both improved nontarget organ clearance and higher target organ uptake of Cu-64-CB-TE2A-Y3-TATE compared with Cu-64-TETA-Y3-TATE.
引用
收藏
页码:8674 / 8682
页数:9
相关论文
共 47 条
[1]   A new method for the synthesis of tri-tert-butyl diethylenetriaminepentaacetic acid and its derivatives [J].
Achilefu, S ;
Wilhelm, RR ;
Jimenez, HN ;
Schmidt, MA ;
Srinivasan, A .
JOURNAL OF ORGANIC CHEMISTRY, 2000, 65 (05) :1562-1565
[2]   Effect of molecular charges on renal uptake of 111In-DTPA-conjugated peptides [J].
Akizawa, H ;
Arano, Y ;
Mifune, M ;
Iwado, A ;
Saito, Y ;
Mukai, T ;
Uehara, T ;
Ono, M ;
Fujioka, Y ;
Ogawa, K ;
Kiso, Y ;
Saji, H .
NUCLEAR MEDICINE AND BIOLOGY, 2001, 28 (07) :761-768
[3]   Renal metabolism of 111In-DTPA-D-Phe1-octreotide in vivo [J].
Akizawa, H ;
Arano, Y ;
Uezono, T ;
Ono, M ;
Fujioka, Y ;
Uehara, T ;
Yokoyama, A ;
Akaji, K ;
Kiso, Y ;
Koizumi, M ;
Saji, H .
BIOCONJUGATE CHEMISTRY, 1998, 9 (06) :662-670
[4]  
Anderson CJ, 2001, J NUCL MED, V42, P213
[5]  
Anderson CJ, 1998, J NUCL MED, V39, P1944
[6]   POLYAMIDE SUPPORTS FOR POLYPEPTIDE-SYNTHESIS [J].
ATHERTON, E ;
CLIVE, DLJ ;
SHEPPARD, RC .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1975, 97 (22) :6584-6585
[7]   Identification of the soluble in vivo metabolites of indium-111-diethylenetriaminepentaacetic acid-D-Phe-octreotide [J].
Bass, LA ;
Lanahan, MV ;
Duncan, JR ;
Erion, JL ;
Srinivasan, A ;
Schmidt, MA ;
Anderson, CJ .
BIOCONJUGATE CHEMISTRY, 1998, 9 (02) :192-200
[8]   In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver [J].
Bass, LA ;
Wang, M ;
Welch, MJ ;
Anderson, CJ .
BIOCONJUGATE CHEMISTRY, 2000, 11 (04) :527-532
[9]   Correlation of red marrow radiation dosimetry with myelotoxicity:: Empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and clinical settings [J].
Behr, TM ;
Béhé, M ;
Sgouros, G .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2002, 17 (04) :445-464
[10]  
Bernard BF, 1997, J NUCL MED, V38, P1929